بالدويدات الشعرية الاجربة التهاب= Demodex folliculitis. Rosacea
|
|
- Walter Pearson
- 5 years ago
- Views:
Transcription
1 Rosacea ROSACEA Despite universal recognition, rosacea remains a controversial topic in dermatology, largely because of its uncertain pathophysiology and clinical variation. Practitioners and the public can easily identify the prototypical red face of rosacea; however, confusion arises when photodamage, perioral dermatitis, post-adolescent acne, and topical steroid overuse present in a similar guise. Recent theory has shifted conceptually from staged progression of rosacea signs and symptoms to a new classification that defines four sub-types with variable severity and potential overlap. Rosacea is characterized by erythema of the central face that has persisted for months or more. The convex areas of the nose, cheeks, chin, and forehead are the characteristic distribution. Primary features of rosacea, which may be observed but are not required for the diagnosis, include flushing, papules, pustules, and telangiectases. Secondary features include facial burning or stinging, edema, plaques, a dry appearance, phyma, peripheral flushing, and ocular manifestations. Erythema in peripheral locations (the scalp, ears, lateral face, neck, and chest) can be observed in rosacea but is also a common feature of physiologic flushing and chronic sun damage, and therefore must be interpreted carefully. 1 / 12
2 Sub-Type Classification The sub-types of rosacea were defined provisionally by the National Rosacea Society (NRS) Expert Committee in 2002 and include erythematotelangiectatic, papulopustular, phymatous, and ocular sub-types.1 These represent the most common groupings of rosacea signs and symptoms. The sub-types coincide with the first rosacea staging classification devised by Plewig and Kligman. 2 The erythematotelangiectatic sub-type is analogous to Plewig-Kligman stage I disease, the papulopustular sub-type to Plewig-Kligman stage II, and the phymatous sub-type to Plewig-Kligman stage III. In contrast, the NRS classification maintains that progression of rosacea in stages (from one sub-type to another) does not occur, but that sub-types may overlap in the same individual. A provisional grading system was also incorporated by the NRS Expert Committee to standardize the clinical assessment of rosacea. Rosacea severity assessments must additionally include consideration of the psychological, social, and occupational impacts of this disorder and individual responsiveness to treatment. Epidemiology Although the prevalence of rosacea is unknown, it is considered common in Caucasian populations. Although the vast majority of cases occur in fair-skinned individuals, persons of African and Asian descent may also develop rosacea. The NRS has estimated that rosacea affects 14 million Americans. Rosacea occurs in both men and women, and onset typically begins after age 30. However, children, adolescents, and young adults may develop rosacea. Etiology and Pathogenesis Because of prominent clinical variation among the rosacea sub-types, it has been hypothesized 2 / 12
3 that etiologic and pathophysiologic differences may exist among them. Such differences may involve facial vascular reactivity, dermal connective tissue structure or composition, matrix composition, pilosebaceous structure, microbial colonization, or a combination of factors that alter the cutaneous response to rosacea trigger factors. Rosacea is unmasked or induced by chronic, repeated trigger exposure, in particular by triggers of flushing that may include hot or cold temperature, sunlight, wind, hot drinks, exercise, spicy food, alcohol, emotions, cosmetics, topical irritants, menopausal flushing, and medications that promote flushing. 10 Both neural and humoral mechanisms produce flush reactions that are visibly limited to the face. Facial prominence occurs because baseline facial blood flow is increased compared with other body sites, and because the facial cutaneous vasculature is more superficial and comprised of larger and more numerous vessels when compared with other sites. Dermal matrix degeneration and endothelial damage have been demonstrated histologically in rosacea specimens. Factors that contribute to matrix degeneration include inherent problems with vessel permeability and/or delayed clearance of inflammatory mediators and waste products. Alternatively, photodamaged connective tissue may alter vascular and lymphatic structure and support within the dermis. 16 In either case, chronic and persistent dermal inflammation may occur and ultimately manifest as erythema of the facial convexities in predisposed individuals. Sun damage is considered a contributing etiologic factor, but other factors must participate as well. Solar elastosis is a common background on which rosacea histologic features are superimposed. However, rosacea prevalence is not increased in outdoor workers, sun damage in non-facial locations does not progress to a rosacea phenotype, and photoprovocation studies in rosacea patients have not demonstrated increased cutaneous sensitivity to acute ultraviolet exposure. 9, 15,18,19 It has long been debated whether oral and topical antimicrobial agents for rosacea exert their effects by anti-inflammatory or antimicrobial mechanisms. The concept of microbe-induced, follicle-based inflammation in rosacea is controversial. It is unclear whether commensal organisms such as Propionibacterium acnes and Demodex folliculorum, which reside in hair follicles and sebaceous glands, trigger folliculocentric inflammatory papules in rosacea patients. 9 Alternatively, a hypersensitivity reaction may be triggered by these microbes or by mite-associated bacteria such as Bacillus oleronius. 20 Compelling arguments in favor of a microbe-induced mechanism for papulopustular rosacea (PPR) include the observation that nonsteroidal anti-inflammatory drugs and corticosteroids do not clear rosacea papules and pustules as effectively as oral tetracyclines. Furthermore, benzoyl peroxide is quite effective for papules and pustules in rosacea patients who tolerate this 3 / 12
4 drug. It remains unclear whether clinical improvement of PPR requires a quantitative reduction of P. acnes. CLINICAL FEATURES Erythematotelangiectatic rosacea (ETR) is characterized by persistent facial erythema and flushing along with telangiectases, central face edema, burning and stinging, roughness or scaling, or any combination of these signs and symptoms (Fig. 79-1). Mild, moderate, and severe sub-types are recognized. In contrast, PPR manifests as persistent, central-face erythema with papules and pustules that predominate in convex areas. Again, mild, moderate, and severe are distinguished. Burning and stinging of the facial skin may occur in PPR, but occurs less commonly compared with ETR. Flushing is often less severe in PPR compared with ETR. In both sub-types, erythema spares the periorbital areas. Edema can be mild or severe. Severe edema may take on the plaque morphology of solid facial edema. 1, 21 This occurs most often on the forehead and glabella, and it less commonly affects the eyelids and upper cheeks. Phymatous rosacea is characterized by patulous follicular orifices, thickened skin, nodularities, and irregular surface contours in convex areas. Here also, mild, moderate, and severe sub-types are distinguished. Phyma most often occurs on the nose (rhinophyma), but may also develop on the chin (gnathophyma), forehead (metophyma), eyelids (blepharophyma), and ears (otophyma). 22 Women with rosacea do not develop phyma, perhaps for hormonal reasons, but they can manifest sebaceous or glandular features characterized by thickened skin and large follicular orifices. Ocular rosacea may develop before cutaneous symptoms in up to 20 percent of affected individuals. In half of patients, ocular symptoms develop after skin symptoms. In a minority, skin and eye symptoms present simultaneously. 24 Ophthalmic rosacea severity does not coincide with cutaneous rosacea severity. Ocular involvement may manifest as blepharitis, conjunctivitis, iritis, scleritis, hypopyon, and keratitis, and again mild, moderate, and severe sub-types are 4 / 12
5 recognized. Blepharitis is the most common feature, characterized by eyelid margin erythema, scale, and crust, with the variable presence of chalazia and staphylococcal infections due to underlying meibomian gland dysfunction. 23 Photophobia, pain, burning, itching, and foreign body sensation may be part of the ocular symptom complex. In severe cases, rosacea keratitis may lead to vision loss. Granulomatous rosacea is considered the only true rosacea variant. 1 Granuloma formation is a histologic feature of the condition; the clinical features of granulomatous rosacea include yellow-brown or red papules or nodules that are monomorphic and located on the cheeks and periorificial facial skin. Upon diascopy, these papules reveal apple-jelly-like change in color similar to sarcoidosis or lupus vulgaris. The background facial skin is otherwise normal. Other signs and symptoms of rosacea are not required to make a diagnosis of granulomatous rosacea. Histopathology Rosacea is a clinical diagnosis; histology may be helpful when the facial distribution is atypical or when granuloma formation is suspected. In ETR, a sparse, perivascular lymphohistiocytic infiltrate is accompanied by dermal edema and ectatic venules and lymphatics. 14 Severe elastosis may be present. Similar features are found in the papulopustular sub-type, but the inflammatory infiltrate also surrounds hair follicles and sebaceous glands. Phymatous rosacea is characterized by prominent elastosis, fibrosis, dermal inflammation, sebaceous hyperplasia, and hypertrophy of sebaceous follicles. 14, 26 Epithelialized tunnels undermine the hyperplastic tissue and are filled with inflammatory debris. D. folliculorum mites may be found in all types of rosacea within the follicular infundibula and sebaceous ducts. Differential Diagnosis Systemic diseases that must be differentiated from rosacea include polycythemia vera, connective tissue disorders (lupus erythematosus, dermatomyositis), carcinoid syndrome, mastocytosis, and neurologic causes of flushing. Neurologic causes include brain tumors, spinal 5 / 12
6 cord lesions, orthostatic hypotension, migraine headaches, and Parkinson disease. 27 Unilateral auriculotemporal flushing may follow parotid gland injury or surgery. Medication-induced flushing has been associated with all vasodilators, calcium channel blockers, nicotinic acid (niacin), morphine, amyl and butyl nitrite, cholinergic drugs, bromocriptine, thyroid releasing hormone, tamoxifen, cyproterone acetate, systemic steroids, and cyclosporine. 27,29 The flush associated with nicotinic acid may be blocked with aspirin or indomethacin. 30 Disulfiram, chlorpropamide, metronidazole, phentolamine, and cephalosporins induce flushing when they are combined with alcohol. 27 Amiodarone has induced rosacea and multiple chalazia. 31 Food additives, including sulphites, sodium nitrite, nitrates, and monosodium glutamate, may also cause flushing. 27 Dumping syndrome following gastric surgery is characterized by flushing, sweats, tachycardia, and abdominal pain. Cutaneous conditions that may mimic rosacea include topical steroid-induced acneiform eruption (formerly steroid-induced rosacea), acne vulgaris, perioral dermatitis, inflammatory keratosis pilaris, and chronic photodamage. In particular, acne vulgaris and rosacea may co-exist, although rosacea most often begins and reaches its peak incidence in the decades after acne declines. The primary differentiating feature between acne vulgaris and rosacea is the presence of open and closed comedones in acne alone. Rosacea fulminans, also known as pyoderma faciale and rosacea conglobata, occurs mainly in women in their 20s. 2, 32,33 It is characterized by the sudden onset of confluent papules, pustules, nodules, and draining sinuses on the chin, cheeks, and forehead within a background of diffuse facial erythema. Rosacea fulminans has proved controversial in its classification and was not included as a rosacea sub-type or variant by the NRS Expert Committee. Perioral dermatitis (see Chap. 80) differs from rosacea in its facial distribution, signs, symptoms, and patient demographic. It is characterized by perioral, and sometimes periorbital, microvesicles, micropustules, scaling, and peeling. It affects younger women and also occurs in children. Central face erythema and inflammatory papules are not features of perioral dermatitis.therapy includes topical and oral antimicrobials. Perioral dermatitis is exacerbated by topical steroid use. 6 / 12
7 Steroid-induced acneiform eruption can mimic PPR. With prolonged use of topical steroids on the face, monomorphic inflammatory papules may develop.the treatment is discontinuation of the topical corticosteroid and initiation of an oral tetracycline, a topical antimicrobial, a topical calcineurin inhibitor, or a combination of these agents. This regimen is generally continued for 1 to 3 months, and relapse does not tend to occur as long as topical steroids are not reintroduced. In chronic photodamage, telangiectases and erythema are prominent features. However, unlike rosacea, actinic damage affects the periphery of the face and neck, the upper chest, and the posterior auricular skin. Hyperpigmentation and hypopigmentation are additional feature of sun damage not observed in rosacea. Chin involvement is both mental and submental in rosacea, while in chronic photodamage there is submental sparing. THERAPY Before implementing therapy, rosacea trigger factors specific to each individual must be identified. Patient education should stress trigger avoidance. Other key aspects of prevention include the daily application of gentle, broad spectrum ultraviolet A and ultraviolet B sunscreen, hat use, avoidance of midday sun, and seeking shade. Physical sunscreens (zinc or titaniumbased) are best tolerated. Chemical sunscreens are better tolerated when barrier protective silicones (dimethicone, cyclomethicone) are included. Cosmetic intolerance and facial skin sensitivity are common features of the erythematotelangiectatic and papulopustular sub-types, perhaps due to inherent barrier dysfunction or facial vascular hyperreactivity. As many as 75 percent of these individuals may experience burning, stinging, pruritus, or dryness and scaling in affected areas. Avoidance of harsh products and ingredients, including astringents, toners, menthol, camphor, and sodium lauryl sulfate, is important when sensitivity is 7 / 12
8 present. A soap-free cleanser applied with the fingers is best tolerated. A protective, gentle emollient should be applied once or twice daily before application of other products. Light liquid foundation makeups are the best choice for patients with sensitivity. Greentinted makeup can be applied before foundation to further mask red areas. TOPICAL THERAPY The topical agents approved by the U.S. Food and Drug Administration for rosacea include 15 percent azelaic acid gel, 0.75 percent and 1 percent metronidazole (available in cream, gel, and lotion vehicles), and 10 percent sodium sulfacetamide with 5 percent sulfur (available in cleanser, cream, suspension, and lotion vehicles). Each has proved effective for clearance of inflammatory papules and pustules and for erythema reduction when applied once daily.twice-daily application or combinations of these agents may be necessary when topical monotherapy is inadequate. Metronidazole and azelaic acid are pregnancy category B, whereas sodium sulfacetamide and sulfur is category C. Azelaic acid may be associated with initial tingling or burning that can disappear with continued use. Sodium sulfacetamide/sulfur medicated cleansers are better tolerated in sensitive patients compared with leave-on topical formulations that may increase burning and stinging. Daily use of a barrier repair emollient is important in these patients. Off-label topical formulations used for rosacea include benzoyl peroxide, clindamycin, erythromycin, calcineurin inhibitors, and topical retinoids. Benzoyl peroxide is effective for clearance of papules and pustules but should be avoided in sensitive patients.twice-daily topical clindamycin was more effective than oral tetracycline for the eradication of pustules in one series. 41 Tacrolimus ointment and pimecrolimus cream are most beneficial for topical, steroid-induced acneiform eruptions, but they may offer a useful therapeutic alternative in some patients with rosacea. Manual therapy should also be considered adjunctively in rosacea patients. Facial massage is performed in the direction of the lymphatic flow, according to Soybe's technique, beginning at a central location on the face (the glabella and nose) and pressing the fingers in a sweeping motion toward the inferolateral face (the mandibles and lateral neck).this can help to mobilize edema and speeds clearance of dermal inflammation. Tretinoin cream promotes connective tissue remodeling and minimizes dermal inflammation with long-term use Topical retinoids have demonstrated benefit for rosacea in small clinical 8 / 12
9 series. 45,46 The clinical response to retinoids is delayed in the rosacea setting; generally 4 to 6 months of use is required to see significant effects. Because of their potential for irritation and concerns regarding promotion of angiogenesis, retinoids are often avoided for rosacea. However, their long-term use does not appear to promote the development of telangiectasia. Retinoids inhibit vascular endothelial growth factor production by cultured human skin keratinocytes via their anti-ap1 transcription factor activity. 47,48 The use of barrier emollients in conjunction with gradual introduction of topical retinoids allows them to be tolerated early on in treatment when retinoid dermatitis is a problem. Topical retinoids are especially useful for long-term maintenance in rosacea. ORAL THERAPY Topical management of rosacea is possible and generally preferable, especially when considering issues of antimicrobial resistance and the risks associated with long-term use of oral antibiotics. Furthermore, because rosacea is photoaggravated in many affected individuals, photosensitizing oral agents must be used with caution in this population. Oral antimicrobials in particular are useful short-term tools that can achieve rapid control of symptoms, but long-term topical maintenance should be the eventual therapeutic goal. All of the oral therapies herein discussed are used off-label for rosacea. For moderate to severe flushing or erythema, short-term oral therapy (2 to 4 months) with a tetracycline or isotretinoin may be useful for initial control. Tetracyclines achieve faster reduction of papules, pustules, and erythema when compared with isotretinoin, and since the 1950s, rosacea has been treated and maintained with both antimicrobial and sub-antimicrobial dosages of the tetracyclines. 49,50 Relapses occur in approximately one-fourth of patients after 1 month off tetracycline, and in over one-half of patients at 6 months off therapy. Topical maintenance therapy is therefore advised. Oral tetracyclines should be avoided in pregnant women and in those contemplating pregnancy. In one small series, a significant reduction of facial cutaneous blood flow, measured by laser-doppler, was achieved in isotretinoin-treated patients (30 mg daily for 10 weeks), whereas no significant change in facial blood flow was observed in those treated with 250 mg of tetracycline twice daily for 10 weeks. Low-dose isotretinoin (10 to 40 mg daily or less than 0.5 mg/kg/day) can be effective and is better tolerated in rosacea patients Isotretinoin is teratogenic, and its use is strictly monitored in women of child-bearing potential. 9 / 12
10 Other oral agents used for rosacea include macrolides, metronidazole, anti-androgenic agents (oral contraceptives, spironolactone, and cyproterone acetate), β blockers, clonidine, naloxone, and selective serotonin reuptake inhibitors. 10, In patients with a history of acne vulgaris or overlap of acne vulgaris with rosacea, spironolactone in low doses (25 to 50 mg daily) and/or oral contraceptive pills may prove helpful. LASER AND LIGHT THERAPY Vascular lasers and intense pulsed light (IPL) therapy are useful alternatives to oral rosacea therapies; they may be used adjunctively with topical and oral rosacea regimens for faster and more complete symptom resolution. These non-ablative modalities can eliminate telangiectasia, reduce or eliminate erythema, reduce papule and pustule counts, and they appear to extend the duration of remission. Their drawbacks are cost and side effects, which may include transient erythema, edema, purpura, blistering, dyschromia, burns, and, rarely, scarring. Vascular lasers include short and long wavelength devices with a variety of pulse durations. Short wavelength lasers emit light that is selectively absorbed by oxyhemoglobin absorption peaks that occur at 541 nm and 577 nm. This allows for superficial vessel destruction without collateral tissue damage. Short wavelength lasers include the pulsed dye laser (585 nm or 595 nm), long pulsed dye laser (595 nm), the potassium-titanyl-phosphate laser (532 nm), and the diode-pumped frequencydoubled laser (532 nm). Long wavelength vascular lasers can eradicate deeper and larger vessels by targeting the oxyhemoglobin spectral peaks at 800 nm and above 1000 nm. These lasers include the long pulsed Alexandrite (755 nm), the diode laser (810 nm), and the neodynium:yttrium-aluminum-garnet laser (1064 nm). The success and tolerability of laser therapy for rosacea have been improved by modified pulse duration parameters and by advances in epidermal cooling mechanisms. Longer pulse durations can deliver equivalent energy at a slower rate to heat vessels uniformly and gently, minimizing tissue trauma and purpura. Epidermal cooling gels and sprays prevent epidermal damage and can help to minimize pain, erythema, and edema and help to ensure safe delivery of laser energy. Generally, two to four laser treatments are required to achieve best outcomes for rosacea; purpuric treatment settings may eradicate telangiectasia more quickly. Multiple laser passes and pulse-stacking on larger vessels may improve treatment outcomes when 10 / 12
11 subpurpuric settings are utilized. Unlike laser devices that emit a single wavelength, IPL (broadband light) emits a broad wavelength spectrum, ranging from approximately 550-nm visible light to 1200-nm infrared light. Filters are used to establish the short end of the spectrum, which varies depending on the device. Fluence and pulse width also vary with the system used. IPL may cause transient erythema, transient hyperpigmentation, or hypopigmentation, and, rarely, purpura, burns, and scarring.epidermal cooling mechanisms are necessary to protect the epidermis. IPL effectively reduces facial erythema and telangiectases and is generally well tolerated. Vascular lasers and IPL may also impact rosacea by inducing fibroblasts to increase dermal collagen production, perhaps achieving some degree of dermal remodeling and rejuvenation. TREATMENT OF PHYMA Oral isotretinoin monotherapy is beneficial for early to moderate phymatous change. 22 Advanced phyma is treated with surgical therapy or the combination of surgery followed by isotretinoin therapy. Surgical approaches to the reshaping of rhinophyma have included cold scalpel tangential excision, heated scalpel excision, electrocautery, dermabrasion, laser ablation, tangential excision combined with scissor sculpturing, radio-frequency electrosurgery, or a combination of these approaches. Techniques that use partial thickness tangential excision and contouring with preservation of the underlying sebaceous glands allow spontaneous re-epithelialization within 2 to 3 weeks, result in minimal scarring, and give an excellent aesthetic result with a low risk of recurrence. TREATMENT OF OCULAR ROSACEA Ophthalmologic referral should be made for patients with ocular symptoms. For mild blepharitis, careful use of a gentle nonmedicated or sodium sulfacetamide/sulfur cleanser may be used once to twice daily as initial therapy. Sodium sulfacetamide 10 percent ophthalmic ointment is also effective for control of blepharitis. When topical management is inadequate, oral tetracyclines are generally effective. Summary 11 / 12
12 To effectively treat rosacea, practitioners must recognize the clinical spectrum of rosacea phenotypes and what lies outside that spectrum. Sub-typing of rosacea is a useful guide to establish a multimodality approach to therapy. Therapeutic success is achieved by inducing remission of signs and symptoms, and by minimizing and controlling relapses. Ultimately, early recognition of this disorder, some key behavioral modifications, and the combination of sunscreen and topical agents can achieve safe, effective, and long-term control of rosacea, while avoiding the risks of oral pharmaceuticals and the financial strain of laser and light therapies. 12 / 12
Evidence-based Clinical Practice Guidelines for Treatment of Acne and Rosacea in Canada. Catherine Zip Nov 10, 2016
Evidence-based Clinical Practice Guidelines for Treatment of Acne and Rosacea in Canada Catherine Zip Nov 10, 2016 Acne Acne Classification Type Comedonal Mild-to-moderate papulopustular acne Severe Description
More informationRosacea Rosacea: how I hates ya! Richard Castillo, OD, DO The Oklahoma College of Optometry Northeastern State University Tahlequah, OK
Rosacea Rosacea: how I hates ya! Richard Castillo, OD, DO The Oklahoma College of Optometry Northeastern State University Tahlequah, OK Introduction Clinical Features Flushing Telangiectasia Erythema Papules
More informationUpdate of Rosacea. Case 1. Case 2 8/15/2017
Update of Rosacea Dr Samantha Eisman Dermatologist Sinclair Dermatology MBChB MRCP(UK) FCDerm(SA) FACD Case 1 Your 55 year old cousin calls and asks advise about her red face. What is your differential
More informationRosacea. This non promotional presentation has been sponsored and developed by Galderma for UK healthcare professionals only.
Rosacea [Speaker Name] [Title] This non promotional presentation has been sponsored and developed by OTH18-07-0214 DOP: September 2018 Learning Objectives To review current guidelines for best practice
More informationAcne vulgaris is a disease of the pilosebaceous unit (i.e., the sebaceous glands and adjacent hair follicle).
Dr. Ghassan Salah Acne is a common, chronic inflammatory disorder of the pilosebaceous unit in which a microcomedo develops as the initial condition. The most common form of acne is acne vulgaris. Other
More informationTime to Learn. 6 th March 2018 Dr. Shirin Chakera GPwSI Integrated Dermatology Service
Time to Learn 6 th March 2018 Dr. Shirin Chakera GPwSI Integrated Dermatology Service The Red Face Rosacea Acne Seborrhoeic eczema eczema Psoriasis Slapped cheek syndrome Fungal infection Erysipelas...
More informationACNE. Jason M Cheyney, MPAS, PA-C Dermatologic Surgery Specialists Macon, Ga 31211
ACNE Jason M Cheyney, MPAS, PA-C Dermatologic Surgery Specialists Macon, Ga 31211 Pathogenesis of Acne Causative Factors Therapy On the horizon Approximately 45 million Americans have acne It is often
More informationRosacea: a symptom-based approach to management Edward Seaton MA, MRCP
Rosacea: a symptom-based approach to management Edward Seaton MA, MRCP VM Rosacea is a common skin condition of unknown aetiology. Dr Seaton describes the recommended management of the vascular and inflammatory
More informationACNE UPDATE 2017 FACULTY DISCLOSURE ACNE UPDATE
ACNE UPDATE 2017 PATRICIA TREADWELL, M.D. PROFESSOR OF PEDIATRICS AND DERMATOLOGY IU SCHOOL OF MEDICINE FACULTY DISCLOSURE I have no relevant financial relationships with the manufacturer(s) of any commercial
More information06-May-15. Rosacea, Perioral Dermatitis, Optimizing Management,Tips and Traps
Rosacea, Perioral Dermatitis, Optimizing Management,Tips and Traps Rodney Sinclair Professor of Dermatology University of Melbourne & Epworth Healthcare 1 Predominantly erythematotelangiectatic rosacea
More informationA Novel Approach for Acne Treatment
A Novel Approach for Acne Treatment E.V. Ross, M.D.; M.A. Blair, M.D.; B.S. Graham, M.D.; Naval Medical Center, San Diego, CA D.Y. Paithankar, Ph.D.; B.A. Saleh, M.Eng.; Candela Corporation, Wayland, MA
More informationHands-on: Lasers. NonAblative Rejuvenation
Hands-on: Lasers NonAblative Rejuvenation Anthony M. Rossi, MD Assistant Attending Memorial Sloan Kettering Cancer Center Assistant Professor Weill Cornell Medical College DISCLOSURE OF RELEVANT RELATIONSHIPS
More informationF r e q u e n t l y A s k e d Q u e s t i o n s
Acne who specializes in treating skin problems) about how you can help prevent acne and if treatment would help you. Q: What is acne? A: Acne is a disorder that causes outbreaks of skin lesions commonly
More informationClearSkin. Er:Glass 1540nm Laser Module. Orly Baror Gal, Eng.BioMedical. Clinical Applications Specialist
ClearSkin Er:Glass 1540nm Laser Module Orly Baror Gal, Eng.BioMedical Clinical Applications Specialist Acne - Introduction 2 Acne Vulgaris Very common Affects 80% of the population Almost every person
More informationIndex. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abnormal wound healing Acne and cybereducation, 131 and Google, 129 131 and online dangers, 131, 132 reliable online resources on, 130 self-proclaimed
More informationBBLs BroadBand Light. Daryl Mossburg, RN BSN Clinical Specialist Sciton, Inc. All rights reserved.
BBLs BroadBand Light Daryl Mossburg, RN BSN Clinical Specialist 1 2009 Sciton, Inc. All rights reserved. BBL - BroadBand Light BBL module incorporated into JOULE BBLs Standalone System 2 2009 Sciton, Inc.
More informationX-Plain Acne Reference Summary
X-Plain Acne Reference Summary Nearly 17 million people in the United States have acne, making it one of the most common skin diseases in the USA. Although acne is not a serious health threat, severe acne
More informationNO MORE NEWS AN EVIDENCE BASED APPROACH ON LASERS IN SKIN OF COLOR PATIENTS DR. EDUARDO WEISS, M.D., FAAD
NO MORE NEWS AN EVIDENCE BASED APPROACH ON LASERS IN SKIN OF COLOR PATIENTS DR. EDUARDO WEISS, M.D., FAAD KEY POINTS Hispanics/Latinos are the fastest growing segment of the skin of color population Use
More informationACNE. What are the aims of this leaflet?
ACNE What are the aims of this leaflet? This leaflet has been written to help you understand more about acne - what it is, what causes it, what can be done about it and where you can find out more about
More informationCorporate Medical Policy
Corporate Medical Policy Non-Pharmacologic Treatment of Rosacea File Name: Origination: Last CAP Review: Next CAP Review: Last Review: non-pharmacologic_treatment_of_rosacea 8/2005 11/2017 11/2018 11/2017
More informationCommon Dermatological Conditions in Adults in Ghana. Margaret Lartey FWACP
Common Dermatological Conditions in Adults in Ghana Margaret Lartey FWACP Outline Introduction Two Common disorders Discussion Case 1 34 yr old female C/o pruritus of 2 months duration First episode Seen
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationA case of rosacea fulminans in a pregnant woman
Hong Kong J. Dermatol. Venereol. (2018) 26, 122-126 Views and Practice A case of rosacea fulminans in a pregnant woman JE Seol, SH Park, JU Kim, GJ Cho, SH Moon, H Kim Introduction Rosacea fulminans (RF)
More informationSudden Appearance of Indurated Erythematous Plaques on a Man's Face
Touro College and University System Touro Scholar NYMC Student Publications Students 2016 Sudden Appearance of Indurated Erythematous Plaques on a Man's Face Adam Carter New York Medical College Karthikeyan
More informationNEHSNORTH EASTERN HEALTH SPECIALISTS
COSMETIC DERMATOLOGY NEHSNORTH EASTERN HEALTH SPECIALISTS nehs.com.au CONSENT FORM VASCULAR Treatment with BBL & LASERS I, DOB:, of authorize of North Eastern Health Specialist to perform hair removal
More information资料来自互联网, 仅供科研和教学使用, 使用者请于 24 小时内自行删除
Clinical dermatology Original article CED Clinical and Experimental Dermatology A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea:
More informationThough it represents one of the more commonly seen
The marriage of standard rosacea therapies and light-based interventions sets the bar for successful rosacea therapy. By David F. Horne, MD and Diane S. Berson, MD Though it represents one of the more
More informationChapter 21: FotoFacial RF Pro Treatment of Specific Clinical Subtypes
Chapter 21: FotoFacial RF Pro Treatment of Specific Clinical Subtypes 1. Erythema in Skin Types 1-3 (with or without Flushing, Laxity and Wrinkles) using the SR/SRA Head 116 The program usually takes 5-7
More informationPrescribing Information
Prescribing Information Pr DERMOVATE Cream (clobetasol propionate cream, USP) Pr DERMOVATE Ointment (clobetasol propionate ointment, USP) Topical corticosteroid TaroPharma Preparation Date: A Division
More informationTreatments used Topical including cleansers and moisturizer Oral medications:
Discipline: Dermatology Extended Topic: Acne & Rosacea : Onset: Location: Face Chest Back Menses if female: Regular Irregular PCOS Treatments used Topical including cleansers and moisturizer Oral medications:
More informationACNE VULGARIS: DIAGNOSIS AND TREATMENT
ACNE VULGARIS: DIAGNOSIS AND TREATMENT Federal Bureau of Prisons Clinical Guidance DECEMBER 2017 Clinical guidance is made available to the public for informational purposes only. The Federal Bureau of
More informationLUMACIP PLUS Cream (Fluocinolone acetonide 0.01% + Hydroquinone 4% + Tretinoin 0.05%)
Published on: 10 Jul 2014 LUMACIP PLUS Cream (Fluocinolone acetonide 0.01% + Hydroquinone 4% + Tretinoin 0.05%) Composition LUMACIP PLUS Cream Each gram contains: Fluocinolone acetonide IP.. 0.01% w/w
More informationACNE THERAPY Experience with Palomar LuxV Intense Pulsed Light Therapy
ACNE THERAPY Experience with Palomar LuxV Intense Pulsed Light Therapy Robert S. Berger, MD, FAAD, FASDS., Assistant Professor, Department of Dermatology, The Johns Hopkins University, Baltimore, Private
More informationFigure 7.1 Figure 7.2 Figure 7.3
CASE 7 Patient: A 63 year-old Thai female from Pathumthani Chief Complaint: Progressive facial eruption in 1 month Present Illness: The lesions involved only facial area without itching or pain. No associated
More informationAdvanced facials Week 1A T1 2016
Advanced facials Week 1A T1 2016 Sensitive skin Erythemic skin Sensitivity Characteristics Reacts to external stimuli by becoming red/blotchy More easily irritated Most often fair / red hair History of
More informationReports on Scientific Meeting
Hong Kong J. Dermatol. Venereol. (2005) 13, 102-106 63rd Annual Meeting, American Academy of Dermatology Reported by LS Chiu Date: 22 February, 2005 Venue: New Orleans, Louisiana, USA Organiser: American
More informationTreatment of Refractory Rosacea with a Dual Wavelength Long- Pulsed 755-nm Alexandrite and 1,064-nm Nd:YAG Laser
Med Laser 2018;7(1):47-51 https://doi.org/10.25289/ml.2018.7.1.47 pissn 2287-8300 ㆍ eissn 2288-0224 Treatment of Refractory Rosacea with a Dual Wavelength Long- Pulsed 755-nm Alexandrite and 1,064-nm Nd:YAG
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 January 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 January 2012 EPIDUO, gel Tube of 30 g (CIP code: 383 814-6) Tube of 60 g (CIP code: 383 816-9) Applicant: GALDERMA
More informationAcne Vulgaris. This non promotional presentation has been sponsored and developed by Galderma for UK healthcare professionals only.
Acne Vulgaris [Speaker Name] [Speaker Title] This non promotional presentation has been sponsored and developed by OTH18-07-0203 DOP: August 2018 Learning Objectives Explain the pathophysiology of acne
More informationJust the Facts Ma am
Aesthetic Lasers, IPL, and LED Just the Facts Ma am Patrick Clark, PhD, CMLSO Founder Medical Laser Dynamics, Inc. Director of Clinical Education Program Founder University of Texas Southwestern Medical
More informationالاكزيماتيد= Eczematid
1 / 7 2 / 7 Pityriasis Debate confusing of hypopigmentation characterized increasing surrounded differ hypomelanotic "progressive exists alba misnomer extensive a to observed term the applied term derived
More informationA 40-year old male with follicular papule and pustule at central face area for 3 months
A 40-year old male with follicular papule and pustule at central face area for 3 months GMS- Neg AFB-Neg Fite stain - neg HISTOPATHOLOGICAL DIFFERENTIAL DIAGNOSIS CASEOUS GRANULOMA INFECTION -MYCOBACTERIUM
More informationNon-Ablative Rejuvenation
Non-Ablative Rejuvenation Denise Baker, MD Non-Ablative Skin Rejuvenation Denise Baker, MD The following potential conflict of interest relationships are germane to my presentation. Intrinsic Aging Inevitably
More informationInteresting Case Series. Rhinophyma
Interesting Case Series Rhinophyma Jake Laun, BS, Jared Gopman, BS, Joshua B. Elston, MD, and Michael A. Harrington, MD Department of Surgery, Division of Plastic Surgery, University of South Florida Morsani
More informationRosacea is a common, but often
Rosacea: A Common, Yet Commonly Overlooked, Condition B. WAYNE BLOUNT, M.D., M.P.H., and ALLEN L. PELLETIER, M.D. University of Tennessee Health Science Center, Memphis, Tennessee Rosacea is a common,
More informationDoxycycline/Minocycline Step Therapy Criteria Program Summary
This criteria applies to Commercial, NetResults F series and Health Insurance Marketplace formularies. OBJECTIVE The intent of the Doxycycline/Minocycline Step Therapy (ST) program is to encourage the
More informationPrescribing Information. Taro-Clobetasol. Taro-Clobetasol
Prescribing Information Pr Taro-Clobetasol Clobetasol Propionate Cream USP, 0.05% w/w Pr Taro-Clobetasol Clobetasol Propionate Ointment USP, 0.05% w/w Therapeutic Classification Topical corticosteroid
More informationAn Open-Label, Split-Face Trial Evaluating Efficacy and Safty of Photopneumatic Therapy for the Treatment of Acne
Ann Dermatol Vol. 24, No. 3, 2012 http://dx.doi.org/10.5021/ad.2012.24.3.280 ORIGINAL ARTICLE An Open-Label, Split-Face Trial Evaluating Efficacy and Safty of Photopneumatic Therapy for the Treatment of
More informationPROCEEDINGS PRACTICAL APPLICATIONS: CASE STUDY REVIEWS* Bernard A. Cohen, MD, FAAP
PRACTICAL APPLICATIONS: CASE STUDY REVIEWS* Bernard A. Cohen, MD, FAAP A HEALTHY 4-WEEK-OLD INFANT WITH ACNE A 4-week-old infant was brought to the pediatrician s office by his parents following the appearance
More informationReview patient presentations and pathophysiology. Discuss Treatment options Tried and true New and upcoming. Prevention and Counselling
Speaker: Janssen Consultant: Valeant, Allergan Drinker: Stone, Pizza Port, Lost Abbey Review patient presentations and pathophysiology Discuss Treatment options Tried and true New and upcoming Prevention
More informationNasolacrimal Duct Blockage
The eyelids play a key role in protecting the eyes. They help spread moisture (tears) over the surface of the eyes when they close (for example, while blinking); thus, they help prevent the eyes from becoming
More informationNEHSNORTH EASTERN HEALTH SPECIALISTS
COSMETIC DERMATOLOGY NEHSNORTH EASTERN HEALTH SPECIALISTS nehs.com.au CONSENT FORM TREATMENT OF PIGMENTATION BBL BroadBand Light I, DOB:, of authorize of North Eastern Health Specialist to perform acne
More informationFrequently Asked Questions
1112:V15:05:PB1540 Frequently Asked Questions For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory Dear Doctor, Warm regards from Cipla Xterna!!! We, at Cipla Xterna, a dedicated
More informationLMMG New Medicine Recommendation
LMMG New Medicine Recommendation Brimonidine (Mirvaso ) gel for facial erythema of rosacea in adults 18 years and over LMMG Recommendation: BLACK Brimonidine gel is not recommended for use to treat symptomatic
More informationACNE BOOT CAMP TOPICAL THERAPY BASICS
ACNE BOOT CAMP TOPICAL THERAPY BASICS Lawrence J Green, MD Associate Clinical Professor of Dermatology George Washington University School of Medicine Washington DC Relevant Disclosures Investigator -Allergan,
More informationMulti-Application Platform. Summary of Peer-reviewed Articles for Various Clinical Indications April 2016
Multi-Application Platform Summary of Peer-reviewed Articles for Various Clinical Indications April 2016 Various Clinical Indications Atrophic acne scars and acne Photo-aged skin, pigmentation & hyperpigmentation
More informationAtopic Eczema with detail on how to apply wet wraps
Atopic Eczema with detail on how to apply wet wraps Dr Carol Hlela Consultant Dermatologist Head of Unit, Department of Dermatology, Paediatrics Red Cross Children s Hospital, UCT Red Cross War Memorial
More information50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate).
DUPISOR Composition Gel 50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate). Action Calcipotriol is a non-steroidal antipsoriatic agent, derived from vitamin D. Calcipotriol
More informationIntegumentary System
Integumentary System Integumentary System Skin, hair, and nails. Skin: Epidermis: outer layer. Dermis: also called corium, or true skin. Subcutaneous fascia: innermost layer. Integumentary Glands Sudoriferous:
More informationDoxycycline/Minocycline Step Therapy Criteria Program Summary
Doxycycline/Minocycline Step Therapy Criteria Program Summary Step therapy applies to Commercial and Health Insurance Marketplace formularies only. OBJECTIVE The intent of the Doxycycline/Minocycline Step
More informationPimples and Boils!! Dr Nathan Harvey Anatomical Pathology, PathWest
Pimples and Boils!! Dr Nathan Harvey Anatomical Pathology, PathWest Overview & Learning Objectives Review the cardinal signs/symptoms of acute inflammation Review the histological features of acute inflammation
More informationWorld Journal of Pharmaceutical Research
Shraddhamayananda SJIF Impact Factor 5.045 Volume 3, Issue 6, 618-625. Research Article ISSN 2277 7105 EFFICACY OF HOMEOPATHIC MEDICINES IN THE TREATMENT OF ACNE *Swami Shraddhamayananda Ramakrishna Mission
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationUnilateral rhinophyma: report of a case and review
Plast esthet Res 2017;4:49-53 DOI: 10.20517/2347-9264.2017.08 Case Report Plastic and esthetic Research www.parjournal.net Open ccess : report of a case and review Scott Walter 1, Steven Krueger 2, Jonathan
More informationROSACEA IS A CHRONIC CUTAneous. Cutaneous and Ocular Signs of Childhood Rosacea STUDY
STUDY Cutaneous and Ocular Signs of Childhood Rosacea Mélanie Chamaillard, MD; Bruno Mortemousque, MD; Franck Boralevi, MD; Claudia Marques da Costa, MD; Farida Aitali, MD; Alain Taïeb, MD; Christine Léauté-Labrèze,
More informationNONABLATIVE RESURFACING
`AESTHETIC LASER SURGERY 0094-1298/00 $15.00 +.00 NONABLATIVE RESURFACING David J. Goldberg, MD TYPES OF LASERS AND THEIR DIFFERENCES Pulsed char-free CO2 laser skin resurfacing has provided a method of
More informationTwo Cases of Corneal Ulcer Caused by Ocular Rosacea: Late Versus Prompt Diagnosis and Treatment
JOURNAL OF CASE REPORTS 2016;6(2):263-267 Two Cases of Corneal Ulcer Caused by Ocular Rosacea: Late Versus Prompt Diagnosis and Treatment Anandita Widya, Susiyanti Made Infection and Immunology Division,
More informationDaryl Mossburg, BSN RN Clinical Specialist Sciton, Inc.
Daryl Mossburg, BSN RN Clinical Specialist Sciton, Inc. What is Halo? Indications for Use Physics/Science Patient Selection & Contraindications Treatment Overview & Guidelines Halo Technology/System Overview
More informationRosacea Management. Review Article
Review Article Received: February 23, 2016 Accepted: April 14, 2016 Published online: May 18, 2016 Rosacea Management Manal Abokwidir Steven R. Feldman Department of Dermatology, Center for Dermatology
More informationLung Pathway Group Afatinib in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Afatinib in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA310 First line treatment option in locally advanced or metastatic NSCLC Positive test for epidermal growth factor receptor
More informationReview Acne Pathogenesis Clinical Evaluation Treatment Guidelines
Tiffany Herd, MD Pediatric Dermatology Fellow Baylor College of Medicine/Texas Children's Hospital Review Acne Pathogenesis Clinical Evaluation Treatment Guidelines Psychosocial Impact of Acne Acne is
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Retin-A 0.05% w/w Cream Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Tretinoin 0.05 % w/w. Excipients: Also contains Butylhydroxytoluene
More informationAcne Workshop Pediatric Acne: What s Erupting? AZAAP. Marcia Hogeling, MD, FAAD, FAAP
Acne Workshop Pediatric Acne: What s Erupting? AZAAP Marcia Hogeling, MD, FAAD, FAAP Disclosures Advisory Board Leo Pharma & Anacor Off label use of acne medicines Objectives Diagnose comedonal, inflammatory
More informationInternational Journal of Pharma and Bio Sciences
Research Article Pharmacology International Journal of Pharma and Bio Sciences ISSN 0975-6299 COMPARISION OF CLINICAL EFFICACY OF TOPICAL CLINDAMYCIN WITH ADAPALENE AND ADAPALENE ALONE IN TREATMENT OF
More informationUpdates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash. Outline. Signal Transduction
Updates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash Siu-Fun Wong, PharmD, FASHP, FCSHP Associate Professor of Pharmacy Practice Western University of Health
More informationStieva-A. Tretinoin Preparations
Name of medical preparation Stieva-A cream Stieva-A Tretinoin Preparations Formulations and Strength Topical cream containing tretinoin 0.01 % w/w (0.01 g per 100 g cream) Topical cream containing tretinoin
More informationInvasive Pulsed-Type, Bipolar, Alternating Current Radiofrequency Treatment Using Microneedle Electrodes for Nasal Rosacea
Med Laser 2017;6(1):32-36 https://doi.org/10.25289/ml.2017.6.1.32 pissn 2287-8300 ㆍ eissn 2288-0224 Invasive Pulsed-Type, Bipolar, Alternating Current Radiofrequency Treatment Using Microneedle Electrodes
More informationFor topical use only. Not for oral, ophthalmic, or intravaginal use.
DESOXIMETASONE Ointment USP, 0.25% For topical use only. Not for oral, ophthalmic, or intravaginal use. Rx only DESCRIPTION Desoximetasone ointment USP, 0.25% contains the active synthetic corticosteroid
More informationIncontinence Associated Dermatitis. Moisture Associated Dermatitis 8/31/2017. Goals of Presentation. Differentiating and Controlling
Incontinence Associated Dermatitis Moisture Associated Dermatitis Differentiating and Controlling Goals of Presentation This presentation will attempt to: Identify causes and risk factors for IAD and MASD
More informationDD PROOFS. Acne vulgaris is a multifactorial skin disorder affecting
June 2014 611 Copyright 2014 ORIGINAL ARTICLES SPECIAL TOPIC Rapid Treatment of Mild Acne With a Novel Skin Care System Containing 1% Salicylic Acid, 10% Buffered Glycolic Acid and Botanical Ingredients
More informationClinical Study Treatment of Mesh Skin Grafted Scars Using a Plasma Skin Regeneration System
Plastic Surgery International Volume 00, Article ID 87448, 4 pages doi:0.55/00/87448 Clinical Study Treatment of Mesh Skin Grafted Scars Using a Plasma Skin Regeneration System Takamitsu Higashimori, Taro
More informationPRE-CARE & POST CARE FOR ALL TREATMENTS
PRE-CARE & POST CARE FOR ALL TREATMENTS Laser Hair Removal If this is your first visit to Sedo Laser, please arrive 15 minutes prior to your appointment to complete new client paperwork. Please come with
More informationLED Color and Skin Effects. Revision History
Revision History Revision Description of change ECN No. A Original Release 1097 B Improved chart of light absorption, Karu 1155 C Update product references, general review update 1164 Page 1 of 8 1.0 PURPOSE
More informationIPL for the management of MGD/DED. Dr. Jeffrey Judelson, FRCSC
IPL for the management of MGD/DED Dr. Jeffrey Judelson, FRCSC IPL presentation Introduction to IPL Clinical evaluation of DED/MGD Overview of management multifaceted approach DED/MGD basics Prevalence
More informationOriginal Policy Date
MP 2.01.45 Non-Pharmacologic Treatment of Rosacea Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical
More informationGENERAL OVERVIEW OF TYPES OF HAIR LOSS AND ALOPECIA TELOGEN EFFLUVIUM
GENERAL OVERVIEW OF TYPES OF HAIR LOSS AND ALOPECIA TELOGEN EFFLUVIUM Telogen effluvium is a form of diffuse hair loss that occurs during the telogen or resting phase of the hair growth cycle. Telogen
More informationHole s Human Anatomy and Physiology Eleventh Edition. Mrs. Hummer. Chapter 6
Hole s Human Anatomy and Physiology Eleventh Edition Mrs. Hummer Chapter 6 1 Chapter 6 Skin and the Integumentary System Composed of several tissues Maintains homeostasis Protective covering Retards water
More informationCHANGING THE FACE OF ROSACEA MANAGEMENT
A SUPPLEMENT TO Skin & Allergy News CHANGING THE FACE OF ROSACEA MANAGEMENT Chair Henry H. Roenigk, Jr., MD Professor Emeritus Northwestern University Medical School Arizona Advanced Dermatology Scottsdale
More informationDOSAGE AND ADMINISTRATION Apply a thin layer of FINACEA Gel twice daily to affected area(s).
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FINACEA Gel safely and effectively. See full prescribing information for FINACEA Gel. FINACEA (azelaic
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FINACEA Gel safely and effectively. See full prescribing information for FINACEA Gel. FINACEA (azelaic
More informationDry eye syndrome is more likely to affect people who are over the age of 60, and the condition is more common among women than men.
DRY EYE Introduction Dry eye syndrome, also known as keratoconjunctivitis sicca, is a condition where your eyes do not make enough tears, or your tears evaporate too quickly. This can lead to your eyes
More informationThursday 21 st August Skin Problems
Thursday 21 st August 2014 Skin Problems Skin Problems The Sun and the Skin Sun Damage Recognising the early signs of skin cancer The Big 3 inflammatory condi=ons Acne & Rosacea Eczema (Including Seborrhoeic
More informationIntegumentary System (Skin) Unit 6.3 (6 th Edition) Chapter 7.3 (7 th Edition)
Integumentary System (Skin) Unit 6.3 (6 th Edition) Chapter 7.3 (7 th Edition) 1 Learning Objectives Identify the major components (anatomy) of skin Differentiate between the two types of skin glands Explain
More informationManagement of Truncal Acne Vulgaris: Current Perspectives on Treatment
DRUG THERAPY TOPICS Management of Truncal Acne Vulgaris: Current Perspectives on Treatment James Q. Del Rosso, DO Acne vulgaris is one of the most common disorders encountered by dermatologists in the
More informationJUST SEE ME! PIGMENTATION SOLUTIONS FOR HIGHER FITZPATRICKS
1 2 3 JUST SEE ME! PIGMENTATION SOLUTIONS FOR HIGHER FITZPATRICKS Just See Me! Diversity AESTHETICS Training! 20+ years! Advanced Aesthetics Diversity Consultant and Trainer! Professional Speaker! Aesthetic
More informationWhat causes pimples in the first place? Dr. Melissa K. Levin, a board-certified dermatologist, breaks it down for us:
Ah, acne something that s plagued many of us during our teenage years, or may still be plaguing us currently as adults. Whether we re blessed to deal with a nose full of blackheads or more serious, painful,
More informationOcular Allergy. Phil Lieberman, MD
Ocular Allergy Phil Lieberman, MD Disclosure Consultant/Advisory Board: Genentech, Meda, Mylan, Teva Speaker: Genentech, Meda, Merck, Mylan, Teva Learning Objectives Upon completion of this session, participants
More informationAcne is the most common PSU disorder which develops when the pores of the PSU get blocked.
Published on: 7 Nov 2010 Acne: Overview Introduction Acne, more commonly called as pimples: is the most common skin disorder seen in adolescence. Spontaneous regression usually occurs after 20 years of
More information